| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $911,000 | 1 | 5 |
Sells | $458,665 | 20 | 95 |
| Cox John | CEO & President | 1 | $911,000 | 4 | $192,802 | $718,198 |
| Friedl-Naderer Johanna | Chief Commercial Officer | 0 | $0 | 5 | $20,460 | $-20,460 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 0 | $0 | 3 | $60,839 | $-60,839 |
| Beskrovnaya Oxana | Chief Scientific Officer | 0 | $0 | 3 | $73,685 | $-73,685 |
| Kerr Douglas | Chief Medical Officer | 0 | $0 | 5 | $110,879 | $-110,879 |
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Over the last 12 months, insiders at Dyne Therapeutics, Inc. have bought $911,000 and sold $458,665 worth of Dyne Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Dyne Therapeutics, Inc. have bought $12.79M and sold $47.38M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cox John (CEO & President) — $911,000.
The last purchase of 100,000 shares for transaction amount of $911,000 was made by Cox John (CEO & President) on 2025‑07‑14.
| 2025-12-05 | Sale | Cox John | CEO & President | 2,662 0.0019% | $20.72 | $55,157 | -7.67% | |
| 2025-12-05 | Sale | Friedl-Naderer Johanna | Chief Commercial Officer | 144 0.0001% | $20.72 | $2,984 | -7.67% | |
| 2025-12-05 | Sale | Kerr Douglas | Chief Medical Officer | 880 0.0006% | $20.72 | $18,234 | -7.67% | |
| 2025-09-05 | Sale | Cox John | CEO & President | 2,640 0.0018% | $13.41 | $35,402 | +28.31% | |
| 2025-09-05 | Sale | Friedl-Naderer Johanna | Chief Commercial Officer | 144 <0.0001% | $13.41 | $1,931 | +28.31% | |
| 2025-09-05 | Sale | Kerr Douglas | Chief Medical Officer | 873 0.0006% | $13.41 | $11,707 | +28.31% | |
| 2025-09-04 | Sale | Friedl-Naderer Johanna | Chief Commercial Officer | 894 0.0006% | $13.27 | $11,863 | +37.69% | |
| 2025-09-04 | Sale | Kerr Douglas | Chief Medical Officer | 3,552 0.0025% | $13.27 | $47,135 | +37.69% | |
| 2025-07-14 | Cox John | CEO & President | 100,000 0.0722% | $9.11 | $911,000 | +83.67% | ||
| 2025-06-05 | Sale | Cox John | CEO & President | 4,060 0.0034% | $13.35 | $54,201 | +0.43% | |
| 2025-06-05 | Sale | Friedl-Naderer Johanna | Chief Commercial Officer | 146 0.0001% | $13.35 | $1,949 | +0.43% | |
| 2025-06-05 | Sale | Kerr Douglas | Chief Medical Officer | 1,342 0.0011% | $13.35 | $17,916 | +0.43% | |
| 2025-03-13 | Sale | Friedl-Naderer Johanna | Chief Commercial Officer | 143 0.0001% | $12.12 | $1,733 | +8.25% | |
| 2025-03-11 | Sale | Beskrovnaya Oxana | Chief Scientific Officer | 2,153 0.0018% | $11.38 | $24,501 | +5.57% | |
| 2025-03-11 | Sale | Scalzo Richard William | SVP, Head of Finance & Admin. | 1,343 0.0011% | $11.38 | $15,283 | +5.57% | |
| 2025-03-05 | Sale | Beskrovnaya Oxana | Chief Scientific Officer | 1,094 0.0009% | $11.83 | $12,942 | +3.86% | |
| 2025-03-05 | Sale | Cox John | CEO & President | 4,061 0.0035% | $11.83 | $48,042 | +3.86% | |
| 2025-03-05 | Sale | Scalzo Richard William | SVP, Head of Finance & Admin. | 917 0.0008% | $11.83 | $10,848 | +3.86% | |
| 2025-03-05 | Sale | Kerr Douglas | Chief Medical Officer | 1,343 0.0011% | $11.83 | $15,888 | +3.86% | |
| 2025-02-18 | Sale | Beskrovnaya Oxana | Chief Scientific Officer | 2,598 0.0026% | $13.95 | $36,242 | -7.26% |
| Cox John | CEO & President | 196877 0.1217% | $3.54M | 2 | 4 | <0.0001% |
| Beskrovnaya Oxana | Chief Scientific Officer | 195840 0.121% | $3.53M | 0 | 24 | |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 122330 0.0756% | $2.2M | 0 | 32 | |
| Friedl-Naderer Johanna | Chief Commercial Officer | 94729 0.0585% | $1.71M | 0 | 5 | |
| Kerr Douglas | Chief Medical Officer | 87510 0.0541% | $1.58M | 0 | 5 | |
| Litespeed Management, L.L.C. | 10 percent owner | 28507291 17.6183% | $513.13M | 19 | 0 | |
| ECP ControlCo, LLC | 10 percent owner | 14291152 8.8323% | $257.24M | 0 | 1 | |
| FRANKLIN RESOURCES INC | 10 percent owner | 8927023 5.5171% | $160.69M | 0 | 110 | |
| Kersten Dirk | director | 5400545 3.3377% | $97.21M | 3 | 42 | +56.53% |
| VV Manager II, LLC | 10 percent owner | 2880125 1.78% | $51.84M | 1 | 0 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 2805045 1.7336% | $50.49M | 1 | 0 | <0.0001% |
| Logos Global Management LP | 10 percent owner | 1504392 0.9298% | $27.08M | 1 | 0 | <0.0001% |
| HURWITZ EDWARD | 1326313 0.8197% | $23.87M | 2 | 0 | ||
| Atlas Venture Opportunity Fund II, L.P. | director | 934581 0.5776% | $16.82M | 1 | 0 | <0.0001% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 864487 0.5343% | $15.56M | 0 | 9 | |
| Atlas Venture Opportunity Fund I, L.P. | 10 percent owner | 847388 0.5237% | $15.25M | 0 | 1 | |
| FLEXON ROBERT C | President and CEO | 720506 0.4453% | $12.97M | 8 | 0 | |
| Brumm Joshua T | CEO & President | 537998 0.3325% | $9.68M | 0 | 19 | |
| Lubner David Charles | director | 177872 0.1099% | $3.2M | 1 | 0 | |
| Farwell Wildon | Chief Medical Officer | 143222 0.0885% | $2.58M | 0 | 16 | |
| McNeill Jonathan | Chief Business Officer | 132106 0.0816% | $2.38M | 0 | 25 | |
| HIGH SUSANNA GATTI | Chief Operating Officer | 131636 0.0814% | $2.37M | 0 | 21 | |
| Freeland Clint | Exec. VP and CFO | 71894 0.0444% | $1.29M | 3 | 0 | |
| NICHOLS HOLLI | EVP and CFO | 64549 0.0399% | $1.16M | 0 | 1 | |
| Callaway Catherine B. | Exec VP and General Counsel | 63042 0.039% | $1.13M | 1 | 0 | |
| Wood Patrick III | director | 45023 0.0278% | $810,414.00 | 3 | 0 | |
| Stehman-Breen Catherine | director | 35574 0.022% | $640,332.00 | 1 | 0 | |
| Klein Lawrence Otto | director | 35574 0.022% | $640,332.00 | 1 | 0 | |
| HAMMICK PATRICIA A | director | 25000 0.0155% | $450,000.00 | 3 | 0 | |
| Rhodes Jason P | director | 15962 0.0099% | $287,316.00 | 1 | 11 | <0.0001% |
| Stein Jeffrey Scott | director | 15489 0.0096% | $278,802.00 | 1 | 0 | |
| GRIJALVA VICTOR | director | 15000 0.0093% | $270,000.00 | 1 | 0 | |
| TRUBECK WILLIAM L | director | 11000 0.0068% | $198,000.00 | 2 | 0 | |
| ELWARD THOMAS W | director | 5000 0.0031% | $90,000.00 | 1 | 0 | |
| Kuersteiner Richard Lee | director | 2500 0.0015% | $45,000.00 | 1 | 0 | |
| Ackermann Hilary E. | director | 1000 0.0006% | $18,000.00 | 1 | 0 | |
| Incerti Carlo | director | 0 0% | $0 | 0 | 1 |
$11,588,217 | 69 | 42.07% | $2.9B | |
$11,583,737 | 45 | 49.75% | $2.63B | |
$148,770,544 | 34 | 80.63% | $3.33B | |
$5,066,938 | 27 | 26.38% | $3.23B | |
$61,703,557 | 26 | 40.25% | $3.09B | |
$27,105,902 | 21 | -16.06% | $2.83B | |
$137,061,250 | 16 | 23.01% | $3.21B | |
$174,105,409 | 15 | 10.88% | $2.75B | |
$73,814,940 | 15 | -4.77% | $2.67B | |
$92,580,864 | 14 | -1.28% | $3.03B | |
$1,248,715 | 10 | 5.66% | $3.34B | |
$45,445,266 | 9 | -24.96% | $3.05B | |
$130,038,539 | 8 | 26.82% | $2.46B | |
$32,575,266 | 8 | 37.03% | $2.9B | |
Dyne Therapeutics, Inc. (DYN) | $91,589,325 | 7 | -6.97% | $2.91B |
$24,000,085 | 4 | 33.26% | $2.88B | |
$142,493,653 | 3 | 4.30% | $3.09B | |
$5,000,000 | 1 | -22.84% | $2.83B | |
$9,900,000 | 1 | -7.19% | $3.16B |
| Increased Positions | 149 | +95.51% | 46M | +35.28% |
| Decreased Positions | 68 | -43.59% | 19M | -14.48% |
| New Positions | 38 | New | 9M | New |
| Sold Out Positions | 28 | Sold Out | 12M | Sold Out |
| Total Postitions | 237 | +51.92% | 157M | +20.8% |
| Janus Henderson Group Plc | $272,792.00 | 9.1% | 14.75M | +5M | +56.24% | 2025-09-30 |
| Vanguard Group Inc | $180,568.00 | 6.03% | 9.76M | +2M | +27.57% | 2025-09-30 |
| Blackrock, Inc. | $178,246.00 | 5.95% | 9.63M | +2M | +19.27% | 2025-09-30 |
| Atlas Venture Life Science Advisors, Llc | $168,914.00 | 5.64% | 9.13M | 0 | 0% | 2025-09-30 |
| Fcpm Iii Services B.V. | $101,063.00 | 3.37% | 5.46M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $99,935.00 | 3.34% | 5.4M | +108,547 | +2.05% | 2025-09-30 |
| State Street Corp | $97,475.00 | 3.25% | 5.27M | +2M | +57.02% | 2025-09-30 |
| Siren, L.L.C. | $87,490.00 | 2.92% | 4.73M | -107,263 | -2.22% | 2025-09-30 |
| Tcg Crossover Management, Llc | $85,380.00 | 2.85% | 4.62M | +848,484 | +22.53% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $65,749.00 | 2.19% | 3.55M | +363,000 | +11.38% | 2025-09-30 |